ZOETIS INC (ZTS) Stock Price, Forecast & Analysis
USA - NYSE:ZTS - US98978V1035 - Common Stock
ZTS Key Statistics, Chart & Performance
The current stock price of ZTS is 121.87 USD. In the past month the price decreased by -16.27%. In the past year, price decreased by -31.41%.
ZTS Latest News, Press Relases and Analysis
ZTS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.82 | 953.69B | ||
| JNJ | JOHNSON & JOHNSON | 18.74 | 468.40B | ||
| MRK | MERCK & CO. INC. | 10.37 | 228.15B | ||
| PFE | PFIZER INC | 8.07 | 146.89B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.53 | 100.59B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.63 | 23.08B | ||
| VTRS | VIATRIS INC | 4.74 | 12.88B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.33 | 11.13B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.41 | 8.29B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.03B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.05 | 4.01B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.04B |
Related stock screener links
About ZTS
Company Profile
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 13,800 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Company Info
ZOETIS INC
10 Sylvan Way
Parsippany NEW JERSEY 07054 US
CEO: Kristin C. Peck
Employees: 13800
Phone: 19738227000
ZOETIS INC / ZTS FAQ
What does ZOETIS INC do?
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 13,800 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
What is the stock price of ZOETIS INC today?
The current stock price of ZTS is 121.87 USD. The price increased by 1.46% in the last trading session.
Does ZOETIS INC pay dividends?
ZOETIS INC (ZTS) has a dividend yield of 1.31%. The yearly dividend amount is currently 1.73.
What is the ChartMill rating of ZOETIS INC stock?
ZTS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for ZTS stock?
24 analysts have analysed ZTS and the average price target is 193.21 USD. This implies a price increase of 58.53% is expected in the next year compared to the current price of 121.87.
Should I buy ZTS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ZTS.
What is the Short Interest ratio of ZOETIS INC (ZTS) stock?
The outstanding short interest for ZOETIS INC (ZTS) is 1.97% of its float.
ZTS Technical Analysis
ZTS Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to ZTS. ZTS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
ZTS Financial Highlights
Over the last trailing twelve months ZTS reported a non-GAAP Earnings per Share(EPS) of 6.34. The EPS increased by 10.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.21% | ||
| ROA | 17.49% | ||
| ROE | 49.11% | ||
| Debt/Equity | 1.31 |
ZTS Forecast & Estimates
24 analysts have analysed ZTS and the average price target is 193.21 USD. This implies a price increase of 58.53% is expected in the next year compared to the current price of 121.87.
For the next year, analysts expect an EPS growth of 8.38% and a revenue growth 2.86% for ZTS